Signal transducer and activator of transcription 3 (STAT3), normally activated by Janus kinase (JAK) in response to cytokine stimulation, has been shown to have oncogenic potential. In addition to JAK, recent data suggest that STAT3 can also be activated by other proteins such as the aberrant fusion protein, NPM-ALK, which is expressed in a subset of systemic anaplastic large cell lymphoma (ALCL). In this study, we investigated the possible role of JAK in activating STAT3 in ALCL using two ALK-positive ALCL cell lines, Karpas 299 and SU-DHL-1. At the steady state, JAK3 showed detectable tyrosine phosphorylation by immunoprecipitation. Treatment with AG490, a JAK inhibitor, decreased but did not completely abrogate tyrosine phosphorylation of JAK3 and STAT3 in a concentration-dependent manner. Similar results were obtained using two other inhibitors of JAK3, WHI-P131 and WHI-P154. These biochemical changes were associated with apoptosis in both cell lines that was coupled with activation of caspase 3 and decreased bcl-xL and bcl-2. Cell cycle analysis revealed a decrease in the S phase, which may be attributed to cyclin D3 downregulation and p21 waf1 upregulation. Importantly, the tyrosine kinase activity of NPM-ALK, as assessed by an in vitro assay, decreased with increasing concentrations of AG490. Our findings highlight the importance of JAK3 in activating STAT3 in ALCL, and that NPM-ALKmediated activation of STAT3 is influenced by the functional status of JAK3.
Introduction
Anaplastic large cell lymphoma (ALCL) constitutes 3% and 10-30% of adult and pediatric lymphomas, respectively (Delsol et al., 2001 ). It was originally described in 1985 as a lymphoma previously known as malignant histiocytosis (Stein et al., 1985) . Thereafter, it was found that ALCL arises from lymphoid cells of T/ null lineage, with consistent expression of CD30 (Ki-1). Based on the aberrant expression of the anaplastic lymphoma kinase (ALK), ALCL is divided into two groups (Delsol et al., 2001 ). Compared to ALK-negative ALCL, ALK-positive cases are more likely to involve younger patients and have a better prognosis (Shiota et al., 1995; Falini et al., 1999; Gascoyne et al., 1999) . The expression of ALK results from several chromosomal aberrations involving the ALK gene on chromosome 2p23, with the t(2;5)(p23;q35) being the most frequent abnormality. This specific chromosomal abnormality fuses the NPM (nucleophosmin) gene on chromosome 5 with the ALK gene, resulting in the production of a fusion gene product, NPM-ALK (Morris et al., 1994) .
NPM-ALK has been shown to be oncogenic (Fujimoto et al., 1996; Ma et al., 2000) , but the mechanism is not completely understood. NPM is a nonribosomal RNA-binding protein, whose functions include the bidirectional shuttling of proteins between the nucleolus and the cytoplasm (Borer et al., 1989) . Its pathogenetic role in ALCL is believed to originate from its ability to form oligomerization, thereby bringing ALK molecules together and leading to autophosphorylation and activation of the ALK tyrosine kinase activity (Bischof et al., 1997) . There is evidence that NPM-ALK mediates oncogenesis via tyrosine phosphorylation/activation of various protein targets, such as Grb2, Shc, IRS-1, PLCg, and PI3K (Bischof et al., 1997; Bai et al., 1998 Bai et al., , 2000 Slupianek et al., 2001) .
The signal transducers and activators of transcription (STATs) family consists of seven transcriptional factors that often participate in regulating cell survival or death (Bromberg, 2002) . Recently, STAT3 has received significant attention with respect to its role in regulating various cellular functions (Minami et al., 1996; Huang et al., 2000; Kijima et al., 2002) and in oncogenesis (Bromberg et al., 1999) . Activation of STAT3 is normally mediated by phosphorylation of the tyrosine 705 residue by Janus kinases (JAKs) upon cytokine stimulation (Bromberg, 2002) . The phosphorylated form of STAT3 (pSTAT3) dimerizes, translocates to the nucleus, and binds to specific consensus DNA sequences, where it is involved in modulating the transcription of a number of genes including c-jun, c-kit, c-myc, bcl-xL, bax, bcl-2, mcl-1, p21 waf1 , and p27 kip1 (Naka et al., 1998; Coqueret and Gascan, 2000; Grad et al., 2000; Alas and Bonavida, 2001; Bowman et al., 2001; Epling-Burnette et al., 2001a; Ning et al., 2001) . STAT3 has been shown to be an oncogene (Bromberg et al., 1999) . It has been found to be constitutively expressed in a variety of solid tumors and hematopoietic malignancies in humans (Minami et al., 1996; Rane and Reddy, 2002; Zhang et al., 2002) . More recently, it has been shown that NPM-ALK binds and activates STAT3 (Zamo et al., 2002) . This finding implicates that ALK may exert its oncogenic effect via STAT3. While there is evidence that NPM-ALK contributes to STAT3 activation, it remains possible that JAK, the physiologic activator of STAT3, may also contribute to STAT3 activation in ALCL. In the present study, we tested the hypothesis that JAK may contribute to STAT3 activation in ALCL using two ALK-positive ALCL cell lines, Karpas 299 and SU-DHL-1. We found that inhibition of JAK3 using decreased, but not completely abrogated, STAT3 activation and AG490 induced caspase 3-associated apoptosis and G 1 cell cycle arrest in both ALCL cell lines. Similar results were obtained with two additional JAK3 inhibitors, WHI-P131 and WHI-154. Importantly, the tyrosine kinase activity of NPM-ALK decreased with AG490 treatment. Our data suggest that JAK3 contributes to STAT3 activation in ALCL and NPM-ALK-mediated activation of STAT3 is influenced by the functional status of JAK3.
Results

AG490 decreased the viability of ALCL cells
To determine if functional blockade of JAK3 has significant biological effects on ALK-positive ALCL cell lines, we treated Karpas 299 and SU-DHL-1 with increasing concentrations of AG490 at 0, 20, 40, or 80 mm. Cells treated with DMSO at a volume equivalent to that used at a concentration of 80 mm of AG490 served as negative controls. The number of viable cells was determined by manual counting of trypan bluestained cells at 72 h after AG490 treatment. The results are summarized in Figure 1 . Both cell lines demonstrated a concentration-dependent decrease in the number of viable cells, with 20 mm being the concentration to induce approximately 50% reduction of the number of viable cells.
AG490-induced apoptosis and G1 cell cycle arrest
To determine whether the decrease in viable cells induced by AG490 treatment was secondary to apoptosis and/or cell cycle arrest, we performed assays to detect the presence of apoptosis and to analyse the cell cycle status. Morphologic examination of the Hoechst-stained cell preparations revealed that both cell lines showed evidence of apoptosis 72 h after treatment with 80 mm of AG490. Figure 2 illustrates that many SU-DHL-1 cells showed nuclear condensation and fragmentation at 72 h after treatment with 80 mm of AG490, and the percentage of apoptotic cells was 8379% after AG490 treatment and 875% with DMSO only. Flow cytometric analysis of annexin V surface binding after AG490 treatment showed that there was a concentration-dependent increase in the binding of annexin V in both cell lines. Figure 3a illustrates the increase in annexin V expression in SU-DHL-1 at 12 h after treating the cells with AG490 at 0, 40, and 80 mm. Figure 3b shows similar results using WHI-P131 and WHI-P154, two additional JAK3 inhibitors at a concentration of 20 mm.
Cell cycle analysis by flow cytometry using bromodeoxyuridine (BrdU) incorporation and 7-amino-actinomycin D (7-AAD) showed that AG490 induced a reduction in the S phase in both cell lines. As shown in Figure 4 , the size of the SU-DHL-1 cell population in the S phase (denoted by a black arrow) decreased with increasing concentrations of AG490; the S-phase cell population almost completely disappeared at a concentration of 80 mm.
AG490-induced apoptosis was associated with caspase 3 activation
To investigate the mechanism of AG490-induced apoptosis further, we performed a colorimetric caspase 3 activity assay using SU-DHL-1. As shown in Figure 5 , both the DMSO-treated (negative control) and AG490-treated cells showed increasing amounts of detectable chromogen with time. However, compared to the negative controls, AG490-treated SU-DHL-1 cells showed a significantly higher level of caspase 3 activity, as demonstrated by the significant difference in the slopes of the curves (t-test, Po0.05). The identification of some degree of caspase 3 activity in DMSO-treated cells is not unexpected, since we found that many ALKpositive ALCL tumors have evidence of caspase 3 activation, as shown by immunohistochemistry using an antibody specific for the active form of caspase 3 (manuscript submitted). To investigate the molecular basis underlying the biologic effects of AG490 in ALCL cell lines, we examined the phosphorylation status of the JAK family using immunoprecipitation and an anti-phosphotyrosine antibody. Using lysates from both cell lines at the steady state, we found that JAK3 showed detectable tyrosine phosphorylation. These results are consistent with previous reports (Zamo et al., 2002) . Using the same technique, we found that AG490 rapidly decreased tyrosine phosphorylation of JAK3 in a concentration-dependent manner in both cell lines. Figure 6a illustrates the results from an immunoprecipitation study using anti-JAK3 antibody and SU-DHL-1 cells: the immunoblots showed a similar level of JAK3 in all treatment conditions, while the reactivity with anti-phosphotyrosine antibody was decreased with increasing AG490 concentrations at 4 h after treatment.
Results from densitometry analysis of each lane summarized the p-tyrosine : JAK3 ratios are also illustrated. Similarly, the extent of tyrosine phosphoryla-
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Figure 2 The caspase 3 activity was measured using a chromogenic-based kinetic assay. The experiment was performed in triplicate. Compared to the negative controls (DMSO-treated cells), AG490-treated SU-DHL-1 cells showed a significantly higher level of caspase 3 activity, as demonstrated by the significant difference in the slopes of the curves (t-test, Po0.05) tion of STAT3 also decreased 4 h after AG490 treatment (Fig. 6b ).
Alterations in downstream targets of JAK/STAT pathway
To evaluate further the mechanism by which AG490 mediates its biological effects on ALCL cells, Western blot studies were used to assess a number of potential downstream targets of STAT3 using ALCL cells 24 h after AG490 treatment. Both cell lines showed similar results and those from SU-DHL-1 are illustrated in Figure 7 . Of the three cyclin D family members, we found that only cyclin D3 was detectable in both Karpas 299 and SU-DHL-1 (unpublished data). A slight increase in cyclin D3 was detected at a relatively low concentration of AG490 (20 mm), followed by a decrease to the baseline level at a concentration of 40 mm, and a marked decrease at a concentration of 80 mm. The cyclindependent kinase inhibitor p21 waf1 was upregulated after treatment of cells with AG490 in a concentrationdependent manner. We also examined the protein level of various apoptosis-regulatory proteins, including bcl-2, bcl-xL, Mcl-1, and survivin. There was a decrease in bcl-xL and bcl-2 with increasing doses of AG490 concentration. No detectable changes in the protein level were seen for Mcl-1 and survivin (data not shown).
NPM-ALK tyrosine kinase activity
We then examined if AG490 has any effects on the tyrosine phosphorylation and tyrosine kinase activity of NPM-ALK. As shown in Figure 8 , SU-DHL-1 cells showed a concentration-dependent decrease in the tyrosine kinase activity of NPM-ALK 4 h after AG490 treatment. At a concentration of 40 mm, the tyrosine kinase activity decreased to approximately 50% of the baseline level. At a concentration of 80 mm, the tyrosine kinase activity level decreased to roughly 30% of the baseline level. Using immunoprecipitation, there was no detectable change in the tyrosine phosphorylation of NPM-ALK 4 h after AG490 treatment (data not shown).
Coimmunoprecipitation study for JAK3 and ALK
To examine the possibility that JAK3 may regulate the tyrosine kinase activity of NPM-ALK via physical association, we performed coimmunoprecipitation studies using anti-JAK3 antibody for immunoprecipitation and anti-ALK antibody for immunoblotting. 
Effects of other JAK3 inhibitors in Karpas 299 and SU-DHL-1
In order to support further the role of JAK3 in activating STAT3 and promoting cell growth in ALCL cells, we employed two additional JAK3 inhibitors, WHI-P131 and WHI-P154, to evaluate if STAT3 phosphorylation can be reduced and if the cell growth can be hindered. As shown in Figure 10a and b, there was a dose-dependent decrease in the phosphorylation level of STAT3 and JAK3 after treatment with WHI-P131 and WHI-P154 in SU-DHL-1 and Karpas 299 cells. Additional studies also showed that these two inhibitors induced apoptosis and cell cycle arrest, similar to AG490, some of the results are shown in Fig. 3(b) .
Discussion
Most cases of ALK-positive ALCL have the characteristic chromosomal aberration, t(2;5)(p23;q35) that results in the aberrant expression of a fusion protein containing a portion of NPM and the tyrosine kinase domain of ALK (Morris et al., 1994) . NPM-ALK has been shown to be oncogenic (Fujimoto et al., 1996; Ma et al., 2000) and its oncogenic potential is believed to be mostly attributed to ALK activity . Although the mechanism underlying the oncogenic potential of NPM-ALK is not completely understood, it has been demonstrated that NPM-ALK interferes with multiple signaling pathways, one of which is the JAK/STAT pathway (Zamo et al., 2002) . Since STAT3 has oncogenic potential (Bromberg et al., 1999) , it is possible that NPM-ALK may exert its oncogenic effect via STAT3. In keeping with this concept, previous studies showed that blockage of the JAK/STAT pathway results in the inhibition of cell growth in a variety of (Imada and Leonard, 2000; Levy and Darnell, 2002) . We found that JAK3 is phosphorylated in ALKpositive ALCL cell lines. A similar observation was recently published by Zamo et al (2002) . This finding suggests that JAK3 is activated in these two ALKpositive ALCL cell lines, although the exact mechanism is not known. As JAK3 is the normal physiologic activator of STAT3, the finding of JAK3 activation in these cell lines raises the possibility that STAT3 may be activated by both NPM-ALK and JAK3. Thus, in the present study, we evaluated the possible role of JAK3 in activating STAT3 and the biologic importance of JAK3 in these cell lines. Our approach was to use AG490 to block JAK3 functionally and assess changes in the tyrosine phosphorylation in JAK3 and STAT3, as well as changes in cell growth and survival.
AG490, a JAK inhibitor, has been previously shown to induce apoptosis in a variety of cell lines (Burke et al., 2001; Kirken et al., 2001; Liu and Kern, 2002) . AG490 has also been shown to induce inhibition of the JAK-STAT pathway as well as apoptotic cell death in several hematopoietic cells (Nielsen et al., 1997; Wang et al., 1999; Epling-Burnette et al., 2001a; Eriksen et al, 2001; Kube et al., 2001; Sun et al., 2001) . In this study, we found that AG490 resulted in a concentration-dependent decrease in the number of viable cells, by inducing apoptosis as well as G 1 cell cycle arrest. The presence of apoptosis was supported by morphology, the expression of annexin V, and activation of caspase 3. Immunoprecipitation studies also showed that tyrosine phosphorylation of JAK3 as well as STAT3 were decreased by AG490 in a concentration-dependent manner. Similar findings were obtained when two additional JAK3 inhibitors, WHI-P131 and WHI-P154, were employed. Although these two JAK3 inhibitors were recently developed and are not as extensively investigated as AG490 (Narla et al., 1998; Sudbeck et al., 1999; Uckun et al., 1999) , the experimental data using these two agents further support the conclusion that JAK3 contributes to STAT3 activation and promotes cell growth in ALK-positive ALCL cell lines.
We have also investigated the molecular basis for the occurrence of apoptosis in AG490-treated cells. Since members of the bcl-2 family have been shown to be the downstream targets of the JAK/STAT pathway (Grad et al., 2000; Alas and Bonavida, 2001; Epling-Burnette et al., 2001a) , we surveyed the expression of a panel of apoptosis-related proteins before and after AG490 treatment. Induction of AG490-mediated apoptosis in these two ALCL cell lines was associated with decreased levels of two antiapoptotic proteins, bcl-xL and bcl-2, suggesting their importance in mediating STAT3-mediated antiapoptotic effects. In contrast, Mcl-1 and survivin did not show significant changes in their protein levels after AG490. Nevertheless, it is of interest to note that Mcl-1 has been suggested to be an important downstream target of the JAK/STAT pathway and to mediate antiapoptotic effect in large granular lymphocyte leukemias, and AG490 treatment in these cells induced downregulation of Mcl-1, but not bclxL or bcl-2 (Epling- Burnette et al., 2001b) . Survivin also has been shown to be an important antiapoptotic protein (Altieri, 2001) , and there is evidence that survivin is important in endothelial cells for inducing IL-11-mediated cell survival in an STAT3-dependent manner (Mahboubi et al., 2001) . A recent study has also shown that inhibition of STAT3 induced apoptosis secondary to decreased survivin expression in primary effusion lymphoma, and the apoptotic effects did not link to changes in bcl-xL, bcl-2, or Mcl-1 (Aoki et al., 2003) . Thus, the significance of various apoptosis-related proteins in inducing STAT3-mediated antiapoptotic effects likely varies among different cell types and/or experimental conditions. Another possibility is that these antiapoptotic proteins are regulated by multiple pathways. For instance, Mcl-1 has been shown to be regulated by both the JAK/STAT and phosphatidylinositol 3-kinase pathways (Epling-Burnette et al., 2001b) . A recent study showed that the phosphatidylinositol 3-kinase pathway is more important than STAT3 in upregulating Mcl-1 in cervical cancer cell lines (Wei et al., 2001) . Thus, inhibition of JAK/STAT alone may not be sufficient in downregulating Mcl-1. Lastly, we also consider the fact that AG490-mediated inhibition of STAT3 in the ALCL cell lines was only partial; activation of STAT3 by the other mechanisms such as NPM-ALK may be sufficient to prevent downregulation of Mcl-1 and survivin in these cell lines.
STAT3 has been shown to facilitate cell cycle progression by upregulating members of the cyclin D family and downregulating G 1 cell cycle inhibitors such as p21 waf1 (Fukada et al., 1998) . Our findings of cyclin D3 downregulation and p21 waf1 upregulation that were associated with AG490-mediated G 1 cell cycle arrest are in keeping with this concept. We did not examine cyclin D1 or cyclin D2, because we did not detect these two proteins by Western blots in Karpas 299 and SU-DHL-1 (unpublished observations). Thus, cyclin D3 probably plays a key role in promoting cell cycle progression from the G 1 to S phase in these cell lines. In support of this view, complete abrogation of cyclin D3 expression (Figure 7 ) by AG490 at a concentration of 80 mm correlated with a dramatic reduction in the proportion of cells present in S phase (Figure 4) . It is of note that our finding of cyclin D3, but not cyclin D1 or cyclin D2, in these two ALCL cell lines is in contrast with the findings of a previous report, which showed cyclin D2 expression in ALK-positive ALCL cell lines (Turturro et al., 2001) . This discrepancy may be due to the differences in specificity and/or sensitivity of the antibodies utilized.
One important finding of this study is that the tyrosine kinase activity of NPM-ALK can be modulated by AG490. We are uncertain as to the exact mechanism, but our results did not show any detectable changes in the tyrosine phosphorylation status of NPM-ALK. One possibility is that AG490 directly interacts with NPM-ALK and inhibits its enzymatic activity. The other possibility is that the tyrosine kinase activity of NPM-ALK is influenced by the functional status of JAK3.
One scenario is that JAK3 physically interacts with both NPM-ALK and STAT3, and the functional status of JAK3 influences the physical interaction of these molecules and hence the degree of STAT3 phosphorylation by NPM-ALK. Our results show that JAK3 and ALK coimmunoprecipitate, which favors such a hypothesis. The other scenario is that JAK3 influences the tyrosine kinase activity of NPM-ALK indirectly via an unknown mediator. Further studies are needed to investigate the functional and physical interactions among NPM-ALK, JAK3, and STAT3.
Using an adenoviral vector carrying dominant-negative STAT3, we recently showed that STAT3 activation is in fact crucial to promoting cell growth (manuscript submitted). Thus, in view of its importance, STAT3 may serve as a therapeutic target for ALK-positive ALCL. Since STAT3 activation is attributed to both JAK3 and NPM-ALK, an alternative therapeutic approach to block STAT3 is to inhibit JAK3 and/or NPM-ALK. While NPM-ALK is an aberrant fusion gene product, JAK3 activation is possibly secondary to cytokine stimulation, which is potentially subjected to immune modulation.
In conclusion, our data highlight the biological importance of JAK3 in promoting cell proliferation and survival in ALCL. In addition to NPM-ALK, JAK3 contributes significantly to STAT3 activation in these cell lines. Our data also suggest that JAK3 may play roles in regulating the tyrosine kinase activity of NPM-ALK, raising the possibility that NPM-ALKmediated STAT3 activation may be dependent on the functional status of JAK3. In view of the importance of the JAK/STAT3 pathway in the pathogenesis of ALKpositive ALCL, both NPM-ALK and JAK3 may serve as potential targets for therapeutic intervention.
Materials and methods
ALK-positive ALCL cell lines
The two ALK-positive ALCL cell lines, Karpas 299 and SU-DHL-1, have been previously characterized and described (Epstein and Kaplan, 1974; Morgan et al., 1989) . Karpas 299 was a generous gift from Dr Marshall Kadin, and SU-DHL-1 was purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ, Germany). The two cell lines were maintained in RPMI 1640 (Life Technologies, Grand Island, NY, USA) supplemented with 10% heatinactivated fetal bovine serum (561C for 30 min), penicillin (10 000 U/ml; Sigma, St Louis, MO, USA), streptomycin (10 mg/ml; Sigma), and l-glutamine (200 mm, 29.2 mg/ml; Life Technologies). All cell cultures were maintained under an atmosphere of 95% oxygen and 5% carbon dioxide in 98% humidity at 371C.
Treatment with JAK3 inhibitors, AG490, WHI-P131, and WHI-P154 AG490, as well as two other JAK3 inhibitors, WHI-P131 and WHI-P154, were purchased from Calbiochem (San Diego, CA, USA). Cell viability, as determined by trypan blue exclusion test, was greater than 90% at the beginning of all experiments.
Cells were washed twice in serum-free RPMI 1640 medium and subjected to DMSO (negative control), and increasing doses of the different inhibitors. The treatment was performed in the dark and the treated cells were kept in the dark throughout the experiments.
Detection of apoptosis
Morphologic changes After AG490 treatment, cell suspensions (100 ml at a concentration of 1.0 Â 10 6 cells/ml) were incubated with 1 ml of Hoechst 33258 (1 mg/ml in distilled water) for 10 min at room temperature. Subsequently, cytospin slides were prepared. After air-drying, cells were examined under a fluorescence microscope. Cells were considered to be apoptotic when the nuclei showed chromatin condensation and fragmentation.
Annexin V detection by flow cytometry Detection of apoptosis was performed after dual staining of the cells with annexin V-PE and 7-ADD in accordance with the manufacturer's protocol. Briefly, 5.0 Â 10 5 cells were washed in ice-cold phosphate-buffered saline (PBS) without Ca 2 þ or Mg 2 þ (Life Technologies). The cells were then suspended in 100 ml of binding buffer and incubated with 5.0 ml of 7-AAD and 2.0 ml of annexin V-PE for 15 min in the dark at room temperature. Flow cytometric analysis was immediately performed using a flow cytometer (Becton Dickinson, San Jose, CA, USA).
Caspase 3 activity assay The functional activity of caspase 3/ CPP32 was detected by using a colorimetric assay (ApoAlert, Clontech, Palo Alto, CA, USA) based on spectrophotometric detection of the chromophore p-nitroanilide (pNA). Briefly, the cells were incubated with AG490 for up to 12 h. The cells were then washed in PBS free of Ca 2 þ and Mg 2 þ and were lysed in cell lysis buffer. The cell lysate was centrifuged at 12 000 rpm for 3 min at 41C to precipitate the cellular debris. Reaction buffer containing DTT and caspase 3/CPP32 substrate (DEVD-pNA) was added to the supernatant. The samples were placed in a 96-well plate and analysed in a plate reader at 405 nm. Both the treated samples and negative controls were run simultaneously in triplicate. Statistical analysis was performed by Student's t-test. Po0.05 was considered to be statistically significant.
Cell cycle analysis by flow cytometry
Cell cycle analysis was performed using a BrdU kit (Becton Dickinson, San Jose, CA, USA) and analysed by a flow cytometer in accordance with the manufacturer's recommended protocol. Briefly, ALCL cells were incubated with BrdU at a final concentration of 10 mm in cell culture medium for 1 h at 371C. After washing in cold PBS, cells were fixed with 100 ml Cytofix/Cytoperm buffer for 15-30 min on ice, and then treated with DNase for 1 h at 371C. After washing, FITClabeled anti-BrdU antibody was incubated with the cells for 20 min at room temperature. After washing, the cells were suspended with 7-AAD and analysed by flow cytometry.
Western blot analysis and immunoprecipitation
The expression of STAT3 and the phosphorylated tyrosine residue (705), in addition to the expression of the following cell cycle-and apoptosis-related proteins was investigated: cyclin D1, cyclin D2, actin D3, p21 waf1 , bcl-2, bcl-xL , Mcl-1, and survivin. With the exception of bcl-2 (Dako, Carpenteria, CA, USA), all the other antibodies were purchased from Santa Cruz (CA, USA). The antibody utilized for the detection of ALK was a mixture of two different antibodies at a ratio of 1 : 1 (Zymed, South San Francisco, CA, USA and Dako). Antibody specific for b-actin was purchased from Sigma. The antibodies were used at dilutions of 1 : 500 to 1 : 1000.
Western blot analysis of the ALCL cell lines was performed using standard techniques. Briefly, the cells were lysed in lysis buffer (20 mm Tris-HCl, pH 7.5, 5.0 mm EDTA, 40.0 mg/ml leupeptin, 1 mm pepstatin, 1 mm 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF)), and centrifuged at 14 000 g for 10 min at 41C. The supernatant was removed and 30 mg of protein was run on an SDS-polyacrylamide gel (PAGE). The proteins were transferred to nitrocellulose membranes and stained with Ponceau S to insure equal protein loading. The membranes were blocked with 5% milk in 20 mm Tris-HCl, pH 7.6, 150 mm NaCl (TBS), stained with primary antibodies for 2 h at room temperature followed by 1 h incubation with horseradish peroxidase-conjugated secondary antibody (Amersham Biosciences, Little Chulfont, Buckinghamshire, UK). The membranes were then washed twice in PBS for 20 min each, 0.05% Tween 20. Proteins were detected using the enhanced chemiluminescence detection kit (Amersham Life Sciences, Arlington Heights, IL, USA). Immunoprecipitation was utilized to identify possible changes in the tyrosine phosphorylation of STAT3 and JAK3 proteins after treatment with AG490.
Coimmunoprecipitation studies
To examine the possible physical association between JAK3 and NPM-ALK, we used anti-JAK3 antibody for immunoprecipitation followed by anti-ALK antibody for immunoblotting. The cell lysates were precleared with agarose beads conjugated with mouse immunoglobulins (Santa Cruz) for 2 h at 41C. The precleared lysates were incubated with primary antibody overnight at 41C. Agarose beads conjugated with protein A/C were then added and incubated for 2 h at 41C. The immunocomplexes were spun down, washed two times with cold PBS (pH ¼ 7.5) and once with lysate buffer, and subjected to SDS-PAGE and Western blotting. Signals were generated using an enhanced chemiluminescence detection kit (Amersham).
Measurement of ALK activity
The activity of NPM-ALK tyrosine kinase was measured using a commercially available kit (Sigma, St Louis, MO, USA) according to the manufacturer's instructions. Cells were lysed with lysis buffer (1% Nonidet P-40, 10% glycerol, 137 nm NaCl, 20 mm Tris buffer (pH 7.4)) containing protease and phosphatase inhibitors (1 mm PMSF, 10 mg/ml pepstatin A, 2 mm sodium vanadate, 20 mm NaF). Immunoprecipitation with 4 ml of ALK goat polyclonal Ab (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and 20 ml of protein A-agarose (Life Technologies, Grand Island, NY, USA) was performed.
Immunoprecipitates were added to poly-Glu-Tyr substratecoated wells. The plate was incubated for 30 min at room temperature in the presence of tyrosine kinase buffer (50 mm HEPES (pH 7.4), 20 mm MgCl 2 , 0.1 mm MnCl 2 , 0.2 mm Na 3 VO 4 , 0.3 mm ATP), washed and incubated with a monoclonal anti-phosphotyrosine/peroxidase conjugate. After washing, the solution containing peroxidase substrate was applied to the plate. The reaction was stopped by adding 2.5 N H 2 SO 4 , and activity was measured in a microplate ELISA reader. The NPM-ALK tyrosine kinase activity 4 h after AG490 treatment was compared to the negative controls (DMSO only), and the results from the treated samples are expressed as fractions of the results from the negative controls.
